| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 22, 2022- New InterStim X™ system provides 10 to 15 years of battery life without the need to recharge
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation...
-
Jan 24, 2022Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval of its Intellis™ rechargeable neurostimulator and...
Jan 14, 2022DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators DUBLIN, Jan. 14, 2022 /PRNewswire/ -- Medtronic plc...
-
Jan 12, 2022
Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain DUBLIN, Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
-
Dec 13, 2021Study shows 57.1% of patients discontinued or reduced oral opioid prescription refills post-procedure and exhibited a decrease in payer costs¹
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International that demonstrate a decrease, and in some cases...